Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPP1R15B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPP1R15B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PPP1R15B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PPP1R15B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPP1R15B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00364904 | Oral cavity | OSCC | regulation of translation in response to endoplasmic reticulum stress | 9/7305 | 11/18723 | 4.85e-03 | 1.92e-02 | 9 |
GO:00069833 | Oral cavity | OSCC | ER overload response | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
GO:0034976110 | Oral cavity | LP | response to endoplasmic reticulum stress | 133/4623 | 256/18723 | 3.84e-21 | 9.24e-19 | 133 |
GO:000641319 | Oral cavity | LP | translational initiation | 75/4623 | 118/18723 | 3.96e-19 | 7.52e-17 | 75 |
GO:0035966110 | Oral cavity | LP | response to topologically incorrect protein | 87/4623 | 159/18723 | 4.31e-16 | 6.28e-14 | 87 |
GO:0006986110 | Oral cavity | LP | response to unfolded protein | 76/4623 | 137/18723 | 1.14e-14 | 1.35e-12 | 76 |
GO:0006979110 | Oral cavity | LP | response to oxidative stress | 181/4623 | 446/18723 | 5.74e-14 | 6.10e-12 | 181 |
GO:000644616 | Oral cavity | LP | regulation of translational initiation | 48/4623 | 79/18723 | 1.04e-11 | 7.66e-10 | 48 |
GO:0035967110 | Oral cavity | LP | cellular response to topologically incorrect protein | 62/4623 | 116/18723 | 2.69e-11 | 1.81e-09 | 62 |
GO:0034620110 | Oral cavity | LP | cellular response to unfolded protein | 53/4623 | 96/18723 | 1.48e-10 | 8.27e-09 | 53 |
GO:0006417110 | Oral cavity | LP | regulation of translation | 175/4623 | 468/18723 | 4.49e-10 | 2.22e-08 | 175 |
GO:0000302110 | Oral cavity | LP | response to reactive oxygen species | 95/4623 | 222/18723 | 2.23e-09 | 9.98e-08 | 95 |
GO:1905897110 | Oral cavity | LP | regulation of response to endoplasmic reticulum stress | 45/4623 | 82/18723 | 4.58e-09 | 1.91e-07 | 45 |
GO:0042542110 | Oral cavity | LP | response to hydrogen peroxide | 68/4623 | 146/18723 | 6.95e-09 | 2.81e-07 | 68 |
GO:000698415 | Oral cavity | LP | ER-nucleus signaling pathway | 30/4623 | 46/18723 | 7.25e-09 | 2.91e-07 | 30 |
GO:003096816 | Oral cavity | LP | endoplasmic reticulum unfolded protein response | 38/4623 | 74/18723 | 6.96e-07 | 1.85e-05 | 38 |
GO:0010563110 | Oral cavity | LP | negative regulation of phosphorus metabolic process | 153/4623 | 442/18723 | 1.47e-06 | 3.53e-05 | 153 |
GO:0045936110 | Oral cavity | LP | negative regulation of phosphate metabolic process | 152/4623 | 441/18723 | 2.10e-06 | 4.77e-05 | 152 |
GO:1903573110 | Oral cavity | LP | negative regulation of response to endoplasmic reticulum stress | 25/4623 | 44/18723 | 5.32e-06 | 1.06e-04 | 25 |
GO:014046712 | Oral cavity | LP | integrated stress response signaling | 15/4623 | 22/18723 | 2.08e-05 | 3.44e-04 | 15 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP1R15B | SNV | Missense_Mutation | novel | c.1677N>A | p.Phe559Leu | p.F559L | Q5SWA1 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
PPP1R15B | SNV | Missense_Mutation | | c.171G>C | p.Glu57Asp | p.E57D | Q5SWA1 | protein_coding | deleterious_low_confidence(0.04) | benign(0.073) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPP1R15B | SNV | Missense_Mutation | | c.1861G>A | p.Asp621Asn | p.D621N | Q5SWA1 | protein_coding | tolerated(0.1) | benign(0.149) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPP1R15B | SNV | Missense_Mutation | | c.1341N>A | p.Asp447Glu | p.D447E | Q5SWA1 | protein_coding | tolerated(0.2) | possibly_damaging(0.693) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPP1R15B | SNV | Missense_Mutation | | c.742N>C | p.Val248Leu | p.V248L | Q5SWA1 | protein_coding | deleterious(0.03) | benign(0.159) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PPP1R15B | SNV | Missense_Mutation | novel | c.1531G>C | p.Glu511Gln | p.E511Q | Q5SWA1 | protein_coding | tolerated(0.3) | benign(0.177) | TCGA-LL-A5YM-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unspecific | letrozole | PD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1228_1229insCC | p.Glu410AlafsTer17 | p.E410Afs*17 | Q5SWA1 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1226_1227insTGGCCTTCCAAAGTGCTGGGATTACAGGCGTG | p.Glu410GlyfsTer27 | p.E410Gfs*27 | Q5SWA1 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1024_1025insGTCCATTGTGGCCATTTCTGAGTGTC | p.Asn342SerfsTer33 | p.N342Sfs*33 | Q5SWA1 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.181_182insTTCTTAGTTGGGAATATTCTGAAAGAATTGGTAGCATAAAGGG | p.Ser61IlefsTer95 | p.S61Ifs*95 | Q5SWA1 | protein_coding | | | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |